Study of CHS-114 in Participants With Advanced Solid Tumors

Active:	Yes
Cancer Type:	Head and Neck Cancer Skin Cancer (Non-Melanoma) Solid Tumor Unknown Primary	NCT ID:	NCT05635643
Trial Phases:	Phase I	Protocol IDs:	SRF114-101 (primary) NCI-2023-05019
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Coherus Biosciences, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05635643

Summary

This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of
SRF114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid
tumors.

Objectives

This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of
CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in participants with
advanced solid tumors, that will be conducted in 3 parts:

- Arm 1a: CHS-114 monotherapy dose-escalation portion of the study will enroll
approximately 25 participants with advanced solid tumors.

- Arm 1b: CHS-114 monotherapy expansion cohort(s) will evaluate the safety, efficacy,
tolerability, pharmacokinetics, and pharmacodynamics of CHS-114 in indication
specific cohort(s). Up to approximately 10 participants will be enrolled.

- Arm 2: CHS-114 + toripalimab combination dose-escalation portion of the study will
evaluate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics
of CHS-114 in combination with toripalimab in indication specific cohort(s). Up to
approximately 6-12 participants will be enrolled.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.